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ABSTRACT ab T cell receptors (TCRs) interact with 
peptides bound to the polymorphic Major 
Histocompatibility Complex class Ia (MHC-Ia) 
and class II (MHC-II) molecules, as well as the 
essentially monomorphic MHC class Ib (MHC-
Ib) molecules. While there is a large amount of 
information on how TCRs engage with MHC-Ia 
and MHC-II, our understanding of TCR-MHC-
Ib interactions is very limited. Infection with 
cytomegalovirus (CMV) can elicit a CD8+ T 
cell response restricted by the human MHC-Ib 
molecule, Human Leukocyte Antigen (HLA)-E, 
and specific for an epitope from UL40 
(VMAPRTLIL), which is characterized by 
biased TRBV14 gene usage. Here we describe 
an HLA-E-restricted CD8+ T cell able to 
recognize an allotypic variant of the UL40 
peptide, with a modification at position 8 (P8) 
of the peptide (VMAPRTLVL) that uses the  
TRBV9 gene segment. We report the structures 
of a TRBV9+ TCR in complex with the HLA-E 
molecule presenting the two peptides. Our data 
revealed that the TRBV9+ TCR adopts a 
different docking mode and molecular footprint 
atop HLA-E when compared with the 
TRBV14+ TCR-HLA-E ternary complex. 
Additionally, despite their differing V gene 
segment usage and different docking 
mechanisms, mutational  analyses showed that 
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the TCRs shared a conserved energetic 
footprint on the HLA-E molecule, focussed 
around the peptide-binding groove. Hence, we 
provide new insights into how monomorphic 
MHC molecules interact with T cells.  
 
Major histocompatibility complex class I (MHC-I) 
molecules perform critical roles in regulating 
innate and adaptive immune responses. These 
molecules have evolved to bind both self and 
pathogen-derived peptides and present them for 
recognition by diverse populations of cells, 
prominently cytotoxic T cells and natural killer 
(NK) cells (1). There are two main classes of 
MHC-I molecules; classical MHC-I (MHC-Ia) that 
constitute the major ligands for CD8+ or cytotoxic 
T cells (CTL) and non-classical MHC-I (MHC-Ib) 
whose functions are less understood but, like their 
classical counterparts are recognized by both the 
adaptive and innate immune systems (2).  
The genes encoding MHC-Ia proteins are 
highly polymorphic, with the polymorphisms 
being primarily clustered around six pockets 
located within the antigen-binding cleft. As 
peptide binding to MHC-Ia proteins is dependent 
on the accommodation of peptide side chains in 
these pockets, variation therein creates allotype-
specific peptide binding properties (3). In contrast 
MHC-Ib genes are far less polymorphic and in 
some cases, such as human leukocyte antigen 
(HLA)-E, essentially dimorphic (4). This restricted 
polymorphism may be associated with the 
additional distinct functions aside from the 
presentation of peptides to CTL. Nevertheless, the 
only identified function of many MHC-Ib 
molecules is the presentation of peptides for T cell 
recognition or the regulation of NK cell activity. 
T cell recognition of MHC-I proteins and 
any associated peptide is mediated by the αβ T 
cell receptor (TCR) via three loops on the α- and β-chain termed complementarity-determining 
regions (CDR). However the majority of the 
current knowledge of peptide recognition by the 
TCR is focused onto MHC-Ia molecules (3). 
Nevertheless there is evidence for distinct roles for 
T cells restricted by MHC-Ib.  For example, in 
mice there are numerous MHC-Ib loci and the 
MHC-Ib molecules Qa-1b, Q9 and H2-M3 have 
been implicated in responses against Salmonella 
typhimurium (5-7) polyoma virus (8) and Listeria 
monocytogenes (9), respectively. Similarly, 
populations of regulatory cells have been shown to 
recognize Qa-1b (10). However it is unclear 
whether these T cells recognize their MHC-Ib 
ligands in an analogous manner to MHC-Ia and 
whether they elicit qualitatively distinct responses 
to pathogens. There is evidence that H2-M3 
restricted T cells are functionally distinct from 
those restricted by MHC-Ia both in terms of 
thymic phenotype and their requirements for 
activation. For example, H2-M3 restricted T cells 
appear to be important in the primary immune 
response following Listeria infection but are not 
expanded upon rechallenge. Furthermore, unlike 
MHC-Ia restricted T cells, H2-M3 restricted T 
cells can be selected on cells of hemopoetic origin 
(11).  
There are far fewer MHC-Ib molecules in 
humans compared to mice (HLA-E –F and –G). 
Of these, the function of HLA-E is perhaps best 
understood. It is the least polymorphic of all HLA 
genes, with 17 alleles described to date, but with 
only two alleles dominating, each being present at 
frequencies of nearly 0.5 (4). Crystal structures of 
HLA-E have revealed a highly restrictive peptide-
binding grove, ideal for accommodating nonamer 
peptides derived from the leader sequence of other 
HLA-I proteins (12-14). Indeed the primary 
function of HLA-E is to present these peptides to 
CD94-NKG2 receptors, thus regulating the 
activity of NK cells. However, HLA-E can also 
present pathogen-derived peptides from 
Salmonella typhimurium (6) Mycobacterium 
tuberculosis (15) and human CMV (16,17) to 
CD8+ T cells. Moreover, infection of macaques 
with engineered CMV vectors that expressed HIV-
I proteins results in HIV-specific, Mamu-E 
restricted CD8+ T cell responses (18). 
Interestingly a CMV epitope from the 
protein UL40 shares an identical amino acid 
sequence with that found in many but not all 
HLA-C derived leader peptides (VMAPRTLIL, or 
“LIL”) and consequently when bound to HLA-E 
can also promote interactions with CD94-NKG2 
receptors (19). In most individuals, the complete 
sequence identity between these HLA-C- and 
UL40- encoded peptides likely results in deletional 
tolerance (20). However, in individuals who lack 
HLA-C alleles that encode the LIL determinant, 
robust UL40-specific, CD8+ T cell responses have 
been observed (17,21). This UL40-specific T cell 
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response to the LIL epitope appears restricted, 
with the TRBV14 gene segment utilized in a 
number of T cell clones isolated from several 
unrelated donors (17,22). 
The structure of a TRBV14+ TCR, called 
KK50.4, was solved in complex with HLA-E-LIL 
and showed that the interaction was broadly 
similar to TCR recognition of MHC-Ia (22). There 
were however a number of distinct features of the 
TCR-HLA-E interaction. In particular, the CDR2b 
loop dominated the contacts made with HLA-E. 
Furthermore, each of the CDR loops of TCRb 
made direct contacts with the Ile at position 8 of 
the peptide (the only peptide residue that differed 
from self-encoded peptides). To date, the 
investigation of T cell responses to UL40 have 
been limited to the prototypical TRBV14+ TCRs 
that recognize the LIL epitope. However, it 
remains unclear whether such features are general 
to TCR recognition of HLA-E/UL40 peptide 
complexes, or to any HLA-E-restricted TCR. 
Previous data suggested that the fine 
specificity of the UL40 T cell response was 
modified by the presence or absence of HLA-A 
alleles in the donor that encoded the sequence 
VMAPRTLVL (“LVL”) (17). Notably in 
individuals lacking LVL as a self-peptide (e.g. 
donors lacking HLA-A2-type leader peptides), the 
UL40 T cell response cross-reacted with the LVL 
peptide. Furthermore, T cells expressing TRBV2 
(Vβ22) or TRBV9 (Vβ1), rather than the typical 
TRBV14 characterized this response. Here, we 
cloned and expressed a TRBV9+ TCR isolated 
from such a donor and report two structures of this 
TCR bound to HLA-E (presenting the LIL and 
LVL peptide). Using mutagenesis we determined 
the energetic contribution of individual HLA-E 
residues interacting with both the TRBV9+ and 
TRBV14+ TCRs. Our data suggests that although 
different TCRs adopt distinct docking modes on 
HLA-E, the energetic basis of the TCR interaction 
is defined by a set of conserved HLA-E residues.  
 
RESULTS 
The GF4 TCR: a non-canonical, TRBV9+, HLA-E 
restricted TCR. 
Previous studies of a canonical TRVB14+ TCR, 
KK50.4, typical of several HLA-E-restricted 
UL40-specific T cell clones expanded in vitro 
from unrelated donors (17,22) demonstrated it to 
be highly specific for the peptide LIL (17). In 
contrast, UL40-specific cells isolated from donor 
GF did not utilise TRBV14, and recognised target 
cells pulsed with both LIL and LVL peptides with 
high avidity (17). To assess whether the molecular 
recognition of HLA-E was conserved between 
TRBV14+ and non-TRBV14 expressing T cells, 
we sequenced and cloned the TCR from a T cell 
clone GF4 obtained from this donor. The GF4 
TCR utilised the TRAV35 and TRBV9 gene 
segments and sequence analysis showed the GF4 
and KK50.4 TCR CDR3 regions have few 
elements in common (Table 1). Moreover, the 
GF4 TCR possessed a longer CDR3β loop than 
the KK50.4 TCR (15 vs 12 amino acids) and 
lacked the conserved Arg110b characteristic of 
TRBV14+ UL40-specific T cell clones (22).  
We then determined the affinity of the 
GF4 TCR for the HLA-E bound to the LIL and 
LVL peptides by surface plasmon resonance 
(SPR). GF4 TCR bound to HLA-E-LIL with an 
affinity of ≈ 37 µM (Fig 1A), and surprisingly 
exhibited a 10-fold higher affinity for HLA-E-
LVL, with a KD ≈ 3 µM (Fig 1B). The higher 
affinity of the GF4 TCR for the LVL peptide 
compared to LIL correlated with a slower 
dissociation rate (Fig 1). As we had previously 
determined that the KK50.4 TCR was highly 
specific for the presence of Ile at P8 (22), the 
sequence differences between the GF4 and 
KK50.4 TCRs impacted their peptide specificity. 
 
GF4 TCR binds to HLA-E molecule with an 
orthogonal docking angle. 
To define the molecular basis of the interaction 
between HLA-E and the GF4 TCR, we determined 
the structures of the GF4 TCR in complex with 
HLA-E presenting both LIL and LVL peptides 
(Table 2). The structures of the two GF4 TCR-
HLA-E complexes were similar, and aligned with 
an overall root mean square deviation (r.m.s.d.) of 
0.49 Å (Fig 2A and 2B). Here, the GF4 TCR 
docked centrally on top of the HLA-E cleft, with a 
docking angle of 88°, whereupon the TCR b- and 
TCR a-chain was positioned above the a1 and a2-
helices, respectively (Fig 2C and 2D). The buried 
surface area (BSA) upon complexation was 
approximately 2,100 Å2, which falls within the 
range of previously observed TCR-pMHC-I 
structures (3).  
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The BSA was equally distributed between 
the GF4 TCR α- and β-chains (Fig 2). All the GF4 
TCR CDR loops were involved in the interaction 
with the HLA-E-peptide complexes (Table 3). The 
CDR1α, CDR1β loops and the α-chain framework 
(FWα) had a small contribution, with a BSA of 
~6%; ~3% and 4%, respectively; followed by the 
CDR2α and the FWβ-region both contributing to 
10% of the BSA. Instead, the interaction was 
driven by the GF4 TCR CDR3α (~30%), CDR3β 
(~19%) and the CDR2β (~19%) loops (Fig 2C and 
2D).  
As the GF4 complexes with both peptides 
were very similar, we analyse below the GF4 
TCR-HLA-E-LVL complex, determined at higher 
resolution (Table 2). The GF4 TCR contacted two 
large stretches of the α1- and α2-helices from 
residues 65-80 and 145-158 (Table 3 and Fig 2C). 
The interaction with the HLA-E α1-helix was 
largely mediated by the GF4 TCR β-chain, (Table 
3).  Here, all three CDR loops along with Arg66β, 
a framework residue, made direct contacts. The 
CDR1β and CDR3β loops formed hydrophobic 
interactions with the HLA-E heavy chain (Fig 3A) 
with Leu37β interacting with Val76 and Pro110β 
binding Arg79 and Thr80 of the HLA-E heavy 
chain. The GF4 TCR also made extensive use of 
CDR2b loop, with four of the six residues 
(56YYNGEE65) alongside Arg66β, an adjacent 
framework (FW) residue all being involved in 
contacting HLA-E. This CDR2-FWβ segment 
abuts an 11 residue long stretch of HLA-E 
(residues 65-76), engaging directly with seven of 
these residues (Table 3). This region of the HLA-E α1-helix is highly charged with four Arg and one 
Asp residue interacting with the two Glu and one 
Arg of the CDR2-FWβ segment, thereby forming 
an extensive salt-bridging network (Table 3 and 
Fig 3B). A large network of hydrogen bonds and 
hydrophobic contacts further strengthened the 
GF4/HLA-E interaction (Table 3).  Here, the 
sidechain of Tyr57β of the CDR2b loop was 
lodged between the Val76 and Ile73 of HLA-E 
forming a peg-notch interaction (Fig 3C). 
Similarly, the side-chain of the FW residue 
Arg66β inserted its guanidinium group between 
the side-chains of the Asp69/Gln72 and the 
CDR3α loop (Fig 3D). Altogether, this highlights 
the important contribution of the GF4 TCR β-
chain in interacting with the HLA-E molecule (Fig 
2C).  
TCR recognition of the HLA-E α2-helix 
was mainly mediated by the TCR α-chain (Table 
3). All three CDRa loops, along with a framework 
residue, Arg84α, contacted the α2-helix (Table 3). 
The GF4 TCR α-chain contacted the centre of the α2-helix, either side of the hinge region spanning 
residues 150-155, highlighting the central docking 
mode of the TCR onto the HLA-E molecule (Fig 
2C). The CDR1α formed hydrophobic interactions 
with the Ala150, Glu154 and His155, as well as 
being within hydrogen bonding distance to the 
main-chain of Ser150 (Fig 3E). Most of the 
CDR2α contacts were mediated via the Tyr57α, 
whose aromatic side-chain lay flat on the hinge of 
the α2-helix, while the FWα residue Arg84α 
formed a salt bridge with the Glu154 (Fig 3E). The 
interactions between the CDR3α loop and HLA-E 
was focused around the His155 residue. The 
107QPLGG111 residues of the CDR3α loop 
surrounded the His155 sidechain, which was 
further caged by the Asn37α and the P5-Arg from 
the peptide. The “cage” surrounding the His155 is 
closed by interaction between Gln107α and 
Glu152 of HLA-E, which fully buried the α2-helix 
residue upon binding of the GF4 TCR (Fig 3F). 
Hence, our structural analysis showed the 
GF4 TCR used all six CDR loops, as well as FW 
residues from both chains, to engage the two 
helices of the HLA-E in an orthogonal docking 
mode. 
 
The GF4 TCR interaction with the LVL and LIL 
peptides is driven by the CDR3α loop. 
The GF4 TCR bound to a large stretch of the 
peptide, ranging from P4-Pro to P9-Leu (Table 3). 
The majority of the contacts were made by the 
CDR3α loop (87% BSA), while the CDR3β loop 
made a smaller contribution (13% BSA) (Table 3). 
The CDR3β formed a salt bridge with the P5-Arg 
via Glu116β, while Pro110β and Asn115β both 
contacted the P8-Val residue in the LVL peptide 
(Fig 4A), and formed similar contacts with the P8-
Ile with the LIL peptide (Table 3). In addition, 
Pro110β made contacts with P9-Leu (Table 3). 
The CDR3α loop made an extensive series of 
contacts, whereupon P5-Arg of the peptide was 
encompassed by the 110GGSNYK115 region of the 
CDR3α loop, and further encaged at the top by 
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Gln107α that was within hydrogen bonding 
distance with P5-Arg. The CDR3α loop was 
positioned above the P4-Pro and the backbone of 
the P6-Thr and P7-Leu. Moreover, Tyr114α 
contacted the side-chain of the P8-Val of the LVL 
peptide, which was also contacted by the Asn113α 
(Fig 4B). As such, the P8-Val was fully buried 
upon binding of the GF4 TCR. Analysis of GF4 
bound to the HLA-E/LIL complex showed a 
similar set of contacts, although the larger P8-Ile 
created a ripple of small structural adjustments 
within the CDR3 loops (Fig 4C) to accommodate 
the additional methyl group, which might be 
sufficiently less favourable for binding to the GF4 
TCR and account for the affinity differences (Fig 
1).  Hence, the GF4 TCR engaged the peptide with 
a large footprint driven by the CDR3α loop.  
 
Structural comparison of KK50.4 TCR and GF4 
TCR in complex with HLA-E. 
 Despite the GF4 and KK50.4 TCRs (22) engaging 
with the same monomorphic HLA-E molecule, the 
differing V gene segment usage (Table 1) between 
the TCRs was associated with  differences in the   
molecular architecture of the TCR/HLA-E 
interaction (Fig 4D). Notably, the KK50.4 TCR is 
heavily reliant (60% of contacts) on the TCR β-
chain to engage with the HLA-E-LIL (Fig 4E) 
(22), while the GF4 TCR uses both chains to a 
similar extent (Fig 4F). The BSA is larger in the 
complex with the GF4 TCR (2100 Å2) compared 
to the KK50.4 TCR (1,800 Å2). Moreover, the 
docking angles are markedly different, with a 
diagonal docking for the KK50.4 TCR (56°) (Fig 
4E) and an orthogonal one for the GF4 TCR (88°) 
(Fig 2C, 2D, 4F). While the centre of mass of the β-chains from each TCRs aligned well (Fig 4E and 
4F), the α-chain of the GF4 TCR made a ~30° 
shift toward the C-terminal end of the antigen-
binding cleft compared to the KK50.4 TCR. In 
addition, while both the α- and β-chains of 
KK50.4 TCR contacted the LIL peptide and the α2-helix of the HLA-E using (Fig 4E), the GF4 
TCR largely used the TCR α-chain to interact with 
these parts of the HLA-E-peptide complex (Fig 
4F).  
The GF4 and KK50.4 TCRs contacted 22 
and 19 HLA-E residues, respectively, fifteen of 
which were shared, albeit interacting with 
different TCR residues (Table 3). Here, the 
CDR2β loops were shifted by ~5 Å between the 
two TCRs. Despite this docking difference, the 
side-chains of two residues (57 and 66) from the 
CDR2b/FWβ segment made similar contacts with 
the HLA-E molecule; the Val57b/Tyr57β of 
KK50.4 and GF4 TCRs, respectively, lodged their 
sidechains between the Ile73 and Val76 of the 
HLA-E molecule (Fig 5C), while the FWβ residue 
at position 66 (Arg/Gln from GF4 and KK50.4 
TCRs, respectively), pointed its sidechain towards 
the Asp69, Gln72 and Ile73 (Fig 5C). 
Although the CDR3α loops of GF4 and 
KK50.4 TCRs were located similarly above P4-
Pro and surrounded the P5-Arg side-chain (Fig 
5A), the GF4 TCR CDR3α loop (BSA of ~30%) 
contributed double the BSA of the KK50.4 TCR 
CDR3α loop (BSA of 14%) (22). This higher 
contribution of the GF4 TCR CDR3α loop was 
associated with Tyr114α sitting above the P8-Val 
residue of the LVL peptide (Fig 5B). However the 
area surrounding the P8 residue of the peptide, 
formed by the CDRβ loops of KK50.4 was larger 
than that in the GF4 TCR, and therefore might 
accommodate a P8-Ile more favourably than a P8-
Val (Fig 5B).   
 The comparison of the GF4 and KK50.4 
structures in complex with HLA-E-peptide 
showed that despite disparate TCR gene usage and 
differing docking strategies, a similar set of HLA-
E and peptide residues formed the TCR 
recognition site.  
 
Shared energetic footprint between KK50.4 and 
GF4 TCRs onto the monomorphic HLA-E 
molecule. 
While both the GF4 and KK50.4 TCRs interacted 
with a similar set of residues on HLA-E, the 
relative energetic contributions of these HLA-E 
residues towards TCR recognition was unclear. 
Consequently, based on the structures of the TCR-
HLA-E-peptide complexes, we mutated the HLA-
E residues engaged by both TCRs (Table 3)  (with 
the exception of Lys146 that is also critical for 
peptide binding) (23). Each residue was 
substituted to an alanine, with the exception of 
Ala150 and Ala158 that were mutated to glycine. 
In addition to the fourteen HLA-E residues 
mutated, we also mutated a residue outside of the 
binding cleft, Thr216, as a negative control. We 
tested the affinity, as determined by SPR, of these 
fifteen HLA-E mutants for both the GF4 and 
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KK50.4 TCRs in presence of their high affinity 
peptides, LVL and LIL respectively (Fig 5D, 5E). 
The impact of each mutation was classified as: no 
effect if the affinity was decreased less than 3-
fold, a moderate effect if the affinity was 
decreased by 3- to 5-fold, or a dramatic impact if 
the affinity by more than 5-fold compare to the 
wild type HLA-E. Firstly, the T216A mutant, used 
as negative control, did not impact the affinity of 
either the GF4 or KK50.4 TCRs.  The affinity 
between wild-type HLA-E and KK50.4 was ~25 
µM (mean of 3 independent experiments: 26.7 ± 
1.3 µM, data not shown), similar to results 
reported previously (22). 
 Of the fifteen substitutions tested, seven 
(R65A, Q72A, R75A, R79A, A150G, E154A and 
R157A) had no significant effect on the affinity of 
interaction with the KK50.4 TCR whereas 
mutation of seven residues (D69A, I73A, V76A, 
T80A, E152A, H155A and A158G) had a marked 
effect upon recognition by KK50.4 TCR (Fig 5D). 
Similarly, seven of these substitutions (R65A, 
D69A, R75A, R79A, A150G, E154A and R157A) 
had little impact on the GF4 TCR binding, with 
one having a moderate impact (A158G) and six 
(Q72A, I73A, V76A, T80A, E152A and H155A) 
dramatically impacting on the affinity of GF4 
TCR for the HLA-E-LVL complex (Fig 5E). 
Noticeably, 11 of the 15 substitutions on the HLA-
E molecule impacted on the affinity in the same 
fashion despite the difference in the interactions 
with the respective TCR-HLA-E interfaces (Fig 4F 
and 4E). Of the substitutions that equally impacted 
on TCRs affinity, five decreased the affinity by 
more than 5-fold, two on the α2-helix E152A and 
H155A, and three on the α1-helix I73A, V76A 
and T80A (Fig 5D and 5E), thereby representing a 
common “hot spot” for recognition by the two 
TCRs with divergent gene usage.  
 
DISCUSSION 
Of the MHC-Ib molecules found in humans, only 
HLA-E has been shown to bind to the ab TCR 
expressed by CD8 T cells. Indeed there has been 
significant interest in HLA-E restricted T cells as a 
result of CMV-vector based vaccination strategies 
that elicit protective Mamu-E-restricted T cell 
responses specific for pathogens such as HIV in 
macaques (18). However, since there is only one 
crystal structure of HLA-E in complex with a 
TCR, our understanding of TCR recognition of 
HLA-E and MHC-Ib molecules more broadly 
remains extremely limited. Here, we describe two 
additional TCR-HLA-E-peptide structures, and 
have assessed the energetic contribution of 
individual HLA-E residues to TCR binding. Our 
findings show different TCR gene usage results in 
distinct TCR docking mechanisms onto HLA-E.  
We had previously observed that the 
affinity of KK50.4 TCR for HLA-E was relatively 
low compared with many other MHC-Ia-virus-
specific TCR (22). We proposed that this in part 
may have been due to the near sequence identity 
between the cognate CMV-derived peptide-ligand 
and self HLA-I-leader sequence encoded peptides 
expressed in the donor thymus that differed by 
only a single methyl group (VMAPRTLIL vs 
VMAPRTLVL).  Donor GF was somewhat 
distinct, lacking HLA-I alleles that encode both 
VMAPRTLIL and VMAPRTLVL. We 
hypothesised that in such donors there is greater 
scope to select TCRs with specificity for CMV-
encoded peptides. This would potentially increase 
the repertoire of TCR and the likelihood of TCR 
with higher affinity for Ag being selected as a 
result of more relaxed negative selection.  
Consistent with this, the GF4 TCR bound the 
HLA-E/LVL complex with significantly higher 
affinity than the KK50.4 bound to the HLA-E/LIL 
complex.  
A number of studies have shown 
polymorphisms in this region of the UL40 gene. 
We reported that only half of the UL40 sequences 
isolated from a cohort of hematopoietic stem cell 
transplant recipients possessed the canonical 
VMAPRTLIL epitope, and the variants 
VMAPRTLLL and VMAPRTLVL were found in 
16% and 12% of patients respectively (15). 
Indeed, while the vast majority of research on 
UL40-specific T cells has focussed on those that 
recognise the canonical VMAPRTLIL peptide, the 
polymorphism in this region of UL40 suggests that 
the capacity to generate HLA-E restricted UL40-
specific T cells may not be strictly limited to 
individuals with specific HLA-C types. The ability 
of individuals to produce such cells will depend 
not only on the HLA-Ia alleles present which 
likely shape the HLA-E restricted, UL40-specific 
repertoire but also on the UL40 sequence present 
within the CMV strain. 
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The different TRAV and TRBV usage as 
well as the altered docking orientations between 
KK50.4 and GF4 indicates that HLA-E is capable 
of selecting T cells that express distinctly different 
TCR into the immune repertoire. Interestingly, 
despite the sequence and structural differences, 
these TCRs utilised a similar energetic hotspot of 
recognition on HLA-E. This is in contrast to 
previous finding of TCR recognition of MHC-Ia, 
where different structural footprints can result in 
altered energetic footprints (23). Significantly, 
here we have demonstrated that approximately 
half of the HLA-E contact residues are critical for 
to binding to both the KK50.4 and GF4 TCRs. 
This in general contrasts the smaller energetic 
footprints that can underpin TCR-MHC-I 
recognition (24,25). Nevertheless, previous studies 
have identified position 155 in the MHC-Ia heavy 
chain, as well as the MHC-II equivalent residue 
70b, as often (but not always) representing a 
critical position for TCR recognition of MHC (26-
29). The loss of KK50.4 and GF4 recognition of 
HLA-E caused by the H155A mutation is 
consistent with the importance of this position.  
HLA-E is more conserved in evolution 
than classical HLA-I, with the gene arising prior to 
primate evolution presumably becoming fixed as a 
consequence of acting as a ligand for CD94-
NKG2 receptors (30,31). We have previously 
assessed the ability of mutant HLA-E molecules to 
interact with the inhibitory NK cell receptor 
CD94-NKG2A and shown that this innate 
recognition of HLA-E was also characterised by a 
broad energetic footprint with 7/11 of the contact 
residues contributing to the binding energy 
(32,33). Given that a large number of HLA-E 
residues are critical to the interaction with both 
NK cell receptors and TCRs, it is possible that the 
energetic principles governing immune 
recognition of MHC-Ib may be more stringent.  In 
any case, our data indicates the rules governing 
TCR recognition of MHC-Ia molecules may not 
always be applicable to the less polymorphic 
MHC-Ib molecules. 
 
EXPERIMENTAL PROCEDURES 
Generation of recombinant HLA-E 
cDNA encoding the extracellular domain of wild-
type HLA-E*0103 and human b2-microglobulin 
(b2m) were cloned into the pET-30 expression 
vector.  The proteins were refolded with the 
synthetic peptide VMAPRTLIL (LIL) or 
VMAPRTLVL (LVL) (GenScript, NJ) as 
described (22). The resulting complexes were 
purified by anion exchange and gel filtration 
chromatography. Mutations were introduced into 
the HLA-E heavy chain by the QuikChange® Site 
Directed Mutagenesis Kit (Stratagene La, Jolla, 
CA) and the sequence of the mutated HLA-E 
cDNA verified by DNA sequencing. HLA-E 
mutants were expressed in E. coli with yields 
similar to the wild type HLA-E and an appearance 
identical to the wild type HLA-E HC when 
inclusion bodies were separated on SDS-PAGE 
(data not shown). Moreover, mutants eluted from 
size exclusion columns at the same volume as wild 
type HLA-E and were each recognised by with the 
pan HLA class I mAb w6/32 and anti-hb2m 
antisera in a capture ELISA (data not shown) (34).  
 
Generation of recombinant TCR 
Soluble, recombinant forms of the UL40-specific 
TCRs, KK50.4 and GF4, were generated 
essentially as described previously (22). Briefly, 
the a and b chains of the TCRs were cloned 
separately into the pET-30 expression vector and 
were expressed and purified from inclusion 
bodies, then refolded by dilution in a buffer 
containing 5M urea. The resulting ab TCR 
complex was purified by anion exchange, gel 
filtration and MonoQ chromatography.  
 
Surface Plasmon Resonance 
Surface plasmon resonance (SPR) experiments 
were performed as previously described (22). 
Experiments were conducted at 25°C either on a 
BIAcore 3000 or Bio-Rad ProteOn instrument at a 
flow rate of 20 µl/min (BIAcore) or 30 µl/min 
(ProteOn). The running and sample buffer was 10 
mM HEPES (pH 7.4), 150 mM NaCl, and 0.05% 
Tween-20 plus 1% BSA to inhibit nonspecific 
binding. The machines yielded consistent binding 
affinities across the different platforms. The 
antibody 12H8 that is specific for the constant 
region of TCR ab (25) was coupled to all flow 
cells of a CM5 (BIAcore) or GLC (ProteOn) chip. 
For each experiment, two different preparations of 
either KK50.4 or GF4 TCR were passed over 2 
different flow cells and ~300-500 RU of the TCR 
was captured by the antibody. The other flow cells 
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served as control cells for the experiments. Wild 
type HLA-E or HLA-E mutants were injected over 
all flow cells at a concentration range of 1.8-100 
µM. The antibody surface was regenerated 
between each analyte injection with ActiSep 
(Sterogene) or glycine-HCl pH 3 (Bio-Rad). All 
measurements were minimally done in duplicate. 
BIAevaluation Version 3.1 or ProteOn Manger 
Version 2.1 was used for data analysis and fitted 
using the 1:1 Langmuir binding model.  
 
Crystallization, data collection and structure 
determination 
Crystals of the GF4 TCR in complex with HLA-E-
LVL (10 mg/mL) or with HLA-E-LIL (10 mg/mL) 
in 10 mM Tris-HCl (pH 8), 150 mM NaCl buffer 
were grown at 20°C by the hanging-drop, vapor-
diffusion method with a protein/reservoir drop 
ratio of 1:1. Crystals of GF4 TCR /HLA-
EVMAPRTLVL and GF4 TCR /HLA-EVMAPRTLIL were 
obtained in 0.2 M K-Na-tartrate, 0.1 M Bis-Tris 
propane, pH 8.0, 20% PEG3350 (w/v). Crystals 
were soaked in a cryoprotectant solution 
containing mother liquor solution supplemented 
with 20 % PEG3350 (w/v) and flash frozen in 
liquid nitrogen. All datasets were collected on the 
MX2 beamlines at the Australian Synchrotron, 
Clayton using the ADSC-Quantum 315r CCD 
detectors (at 100K). Datasets were processed with 
MOSFLM software (35), and scaled using 
SCALA software (ISSN: 0907-4449) from the 
CCP4 suite (36). Both GF4 TCR-HLA-E-LVL and 
GF4 TCR-HLA-E-LIL structures were determined 
by molecular replacement using PHASER 
program with the LC13 TCR (Protein Data Bank 
accession number, 1KGC (37)) and unliganded 
HLA-E VMAPRTLIL (Protein Data Bank 
accession number, 2ESV (22)) as search models.       
Manual model building was conducted using the 
Coot software (38) followed by maximum-
likelihood refinement with Buster (39). The GF4 
TCR was numbered according to the IMGT 
unique numbering system (40). The final models 
were validated using the Protein Data Base 
validation web site and the final refinement 
statistics are presented in Table 1.  Coordinates 
submitted to PDB database, GF4 TCR-HLA-E-
LVL (Code:5W1W). GF4 TCR-HLA-E-LIL 
Code:5W1V). All molecular graphics 
representations were created using PyMol (41). 
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Table 1. Sequences of TCR clones* 
 TCR 
 KK50.4 GF4 
Donor HLA-Ia A02, A32, B44, C07 A01, A03, B27, B44, C02 
TRAV 26-1*01 35*02 
TRAJ 37*02  53*01  
Protein sequence CDR1a TISGNEY SIFNT 
Protein sequence CDR2a GLKNN   LYKAGEL 
Protein sequence CDR3a CIVVRSSNTGKLIF CAGQPLGGSNYKLTF 
TRBV 14*01  9*01  
TRBJ 2-3*01  1-4*01  
Protein sequence CDR1b SGHDN SGDLS 
Protein sequence CDR2b FVKESK YYNGEE 
Protein sequence CDR3b CASSQDRDTQYF CASSANPGDSSNEKLFF 
* IMGT nomenclature (40). 
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Table 2. Data collection and refinement statistics 
 
 Data Collection Statistics GF4 TCR-HLA-E-LIL GF4 TCR-HLA-E-LVL 
Resolution range (Å) 
54.93 — 3.31  
(3.43  — 3.31) 
50.29 — 3.10  
(3.21  — 3.10) 
Space group P212121  P212121 
Unit cell (a, b, c) (Å) 71.64, 228.24, 276.87  73.37, 225.92, 276.26 
Multiplicity 2.0 (2.0) 2.0 (2.0) 
Completeness (%) 99.3 (93.5) 99.8 (100.0) 
I/s(I) 13.35 (2.75) 10.74 (2.06) 
Rmerge
a (%) 5.6 (27.8) 6.1 (33.7) 
Refinement Statistics   
Rfactor
b (%) 22.54 21.49 
Rfree
b (%) 26.81 26.33 
r.s.m.d. from ideality   
Bond lengths (Å) 0.015 0.017 
Bond angles (°) 1.44 1.76 
Ramachandran plot (%)   
favoured 90 93 
outliers 0.85 0.62 
 
a Rmerge = S | Ihkl - < Ihkl > |  / SIhkl. b Rfactor = Shkl  | | Fo | - | Fc | | / Shkl | Fo | for all data except ≈ 5% which 
were used for Rfree calculation. Values in parentheses are for the highest resolution-shell. 
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Table 3.  Contact table of GF4 TCR-HLA-E-LIL, GF4 TCR-HLA-E-LVL and KK50.4 TCR-HLA-E-LIL 
(22) complex interactions.  
HLA-E  GF4-HLA-E-LIL GF4-HLA-E-LVL KK50.4-HLA-E-LIL Type of bond 
R62     R108α  VDW 
R65 R66β, A67β R66β  D67β HB, SB, VDW  
R68 
 
E65β, R66β 
 
HB, SB, VDW  
D69 S112α  S112α  N112α, T113α HB, VDW 
  R66β R66β Q66β HB, VDW 
T70     N112α VDW 
Q72 Y57β, E64β, E65β, R66β Y57β, E64β, E65β, R66β Q66β HB, VDW  
I73 N113α, Y114α N113α, Y114α   VDW 
  Y57β, R66β Y57β, R66β V57β, Q66β VDW 
R75 N58β, E64β N58β, E64β S64β SB, HB, VDW 
V76 L37β, Y57β, N58β, P110β L37β, Y57β, N58β, P110β V57β, S64β VDW 
R79 L37β, P110β L37β, P110β E63β SB, VDW  
T80 P110β P110β K58β VDW 
Q145   S113β 
 
HB, VDW 
K146 
P110β, D112β, S113β, 
N115β P110β, D112β, S113β, N115β D37β HB, SB, VDW 
N148 K58α K58α   HB, VDW 
D149 Y57α Y57α   VDW 
A150 N37α, T38α, Y57α N37α, T38α, Y57α  D109β VDW 
S151 N37α, Y57α, K58α N37α, Y57α, K58α 
 
HB, VDW 
E152   Q107α, N113α  D109β, R110β SB, VDW 
E154 N37α, R84α, L109α N37α, R84α, L109α Y38α, L57α SB, HB, VDW 
H155 
N37α, Q107α, P108α, 
L109α, G110α N37α, Q107α, P108α, L109α, G110α, G111α Y38α, Y40α, S109α, D111β HB, VDW 
R157   R84α L57α VDW 
A158 L109α L109α Y38α VDW 
D162     G30α VDW 
Peptide  GF4-HLA-E-LIL GF4-HLA-E-LVL KK50.4-HLA-E-LIL Type of bond 
P4-Pro G110α, S112α G110α, S112α S109α, S110α VDW 
P5-Arg 
Q107α, 
P108a, G110a,  
G111α, S112α, N113α, 
Y114α 
Q107α, 
P108a, G110a,  
G111α, S112α, N113α, 
Y114α S110α, N111α HB, VDW 
 
E116β E116β N109β, R110β, N112β HB, SB, VDW 
T6 N113α N113α N112α HB, VDW 
  
  
R110β HB, VDW 
L7   N113α   VDW 
I/V8 N113α, Y114α N113α, Y114α 
 
VDW 
  E116β P110β, N115β D37β, N38β, V57β, R110β VDW 
L9 P110α P110α   VDW 
HB: Hydrogen bonds (cut-off at 3.5 Å), SB: Salt bridge (cut-off at 5 Å), VDW: van der Waals (cut-off at 4.5 Å) 
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Figure 1. Representative sensorgrams showing the binding of GF4 TCR to peptides presented by 
HLA-E by surface plasmon resonance. GF4 was captured on the surface of a Bio-Rad ProteOn 
GLC chip by anti TCR mAb 12H8 (25) and assessed for its ability to interact with HLA-E 
presenting the LIL or LVL (A and B, respectively). Increasing concentrations of HLA-E (A: 100, 
40, 16, 6.4 and 2.6 μM and B: 30, 12, 4.8, 1.9 and 0.8 μM) were passed over captured GF4 TCR. 
KD was determined by equilibrium analysis (right panels) and also by kinetic analysis for 
VMAPRTLVL (dashed lines indicate data fit). Data shows representative sensorgrams of at least 
3 experiments with independent preparations of refolded proteins.  
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Figure 2. 
 (A and B) The structure of the HLA-E (yellow cartoon) presenting either LVL (A) or LIL (B) peptides 
(black sticks) to GF4 TCR (α-chain in pink cartoon for LIL, and β-chain in blue cartoon); β2 
microglobulin is represented in grey cartoon.   
(C and D) Structural footprint of GF4 TCR onto HLA-E-LVL (C) or HLA-E-LIL (D). The contribution of 
the CDR loops to the buried surface area (BSA) of pHLA-E is represented for GF4-HLA-E-LVL (C) and 
for GF4-HLA-E-LIL (D) complexes. The HLA-E atoms making contacts with CDR1α (teal), CDR2α 
(green), CDR3α (purple), framework α (pink), CDR1β (red), CDR2β (orange), CDR3β (yellow) or 
framework β (blue) are coloured accordingly to the TCR segment contacted, while the magenta and blue 
spheres represent the centre of mass for the Vα and Vβ respectively.  
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The percentage contribution of the CDR loops and framework regions of the GF4 TCR-HLA-E-LVL (C) 
and GF4 TCR-HLA-E-LIL (D) complexes in binding to the pHLA-E complex is also shown on the pie 
charts. 
 
 
 
 
Figure 3. 
 (A-D) GF4 TCR β-chain interactions with HLA-E (white) via the CDR1β (red) and CDR3β residues 
(yellow), (A) via the CDR2β (orange) frameworkβ (pale blue) (B, C and D).  
(E-F) GF4 TCR α-chain interactions with HLA-E	α2-helix via the CDR1α (teal), CDR2α (green) and 
frameworkα (pale pink) (E), as well as via the CDR3α (purple) on panel (F). 
Residues interacting are depicted in sticks, hydrophobic bonds are shown in blue dashed lines and salt 
bridges or hydrogen bonds are shown in red dashed lines. 
 
 
 
 at CA
RD
IFF U
N
IV
ERSITY
 on January 26, 2018
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
ab TCR Recognition of HLA-E	
	 18 
 
 
 
 
 
 
 
Figure 4. 
(A-C) GF4 TCR interactions with the peptides: LVL peptide (black stick) interactions with CDR3β 
(yellow) (A) and CDR3α (purple) (B). Superimposition of GF4 TCR CDR3 loops in complex with the 
HLA-E-LIL and HLA-E-LVL, with the CDR3α loops in pink, CDR3β loops in blue for the GF4 TCR-
HLA-E-LVL and lighter shade for the GF4 TCR-HLA-E-LIL and the peptides in black (LVL) and grey 
(LIL).  
Residues interacting are depicted in sticks, hydrophobic bonds are shown in blue dashed lines and salt 
bridges are shown in red dashed lines. 
(D) Superimposition of KK50.4 TCR-HLA-E-LIL (green cartoon) and GF4 TCR-HLA-E-LVL (purple 
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cartoon). Structural footprint of KK50.4 TCR onto HLA-E-LIL (E) and GF4 TCR onto HLA-E-LVL (F). 
The pHLA-E atoms making contacts with each TCR are shown in light pink (α-chain) and blue (β-chain). 
The magenta and blue spheres represent the centre of mass for the Vα and Vβ, respectively.  
 
Figure 5. 
Superimposition of the KK50.4 TCR-HLA-E-LIL (green) and GF4 TCR-HLA-E-LVL (purple) 
structures, with the CDR3α loops surrounding the P4-P5 peptides residues (A), and the CDR3 loops 
around the P8 position of the peptides (B). Panel C shows a superposition of the KK50.4 (green) and GF4 
(purple) TCRs CDR2β loops and their interactions with the HLA-E molecule, the lighter shade coloured 
residues are from the frameworkβ segment. The dashed lines indicated the interactions between residues 
in each complex. 
Affinity of HLA-E mutants to KK50.4 TCR (D) or GF4 TCR (E) represented as relative % of the wild 
type (WT) value determined by surface plasmon resonance, as well as the energetic footprints of each 
TCR on HLA-E. Dotted lines represent 30% (or 3 times binding reduction) in orange and 20% (or 5 times 
binding reduction) in red of the binding affinity compared to WT HLA-E. The effect of each mutation 
(yellow no effect, orange 3 times binding reduction and red 5 times binding reduction) is represented on 
the HLA-E surface. Peptides residues are shown in grey. 
 
 at CA
RD
IFF U
N
IV
ERSITY
 on January 26, 2018
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
Cristina Mingari, Lorenzo Moretta, Stephanie Gras, Jamie Rossjohn and Andrew G. Brooks
Wenhwa Sum, Craig S. Clements, Eleanor J. Lee, Travis Beddoe, Michela Falco, Maria 
Lucy C. Sullivan, Nicholas G. Walpole, Carine Farenc, Gabriella Pietra, Matthew J.
 T cell receptorsβαAntigen-E by two distinct 
A conserved energetic footprint underpins recognition of Human Leukocyte
 published online September 25, 2017J. Biol. Chem. 
  
 10.1074/jbc.M117.807719Access the most updated version of this article at doi: 
 Alerts: 
  
 When a correction for this article is posted•  
 When this article is cited•  
 to choose from all of JBC's e-mail alertsClick here
 at CA
RD
IFF U
N
IV
ERSITY
 on January 26, 2018
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
